Larimar Therapeutics Inc (NASDAQ: LRMR)’s stock price has decreased by -10.24 compared to its previous closing price of 2.54. However, the company has seen a -10.59% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-24 that BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
Is It Worth Investing in Larimar Therapeutics Inc (NASDAQ: LRMR) Right Now?
The 36-month beta value for LRMR is also noteworthy at 0.84. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LRMR is 36.46M, and at present, short sellers hold a 13.96% of that float. The average trading volume of LRMR on March 25, 2025 was 616.91K shares.
LRMR’s Market Performance
The stock of Larimar Therapeutics Inc (LRMR) has seen a -10.59% decrease in the past week, with a -28.53% drop in the past month, and a -45.19% fall in the past quarter. The volatility ratio for the week is 9.08%, and the volatility levels for the past 30 days are at 8.54% for LRMR. The simple moving average for the last 20 days is -16.76% for LRMR stock, with a simple moving average of -63.78% for the last 200 days.
Analysts’ Opinion of LRMR
Many brokerage firms have already submitted their reports for LRMR stocks, with Truist repeating the rating for LRMR by listing it as a “Buy.” The predicted price for LRMR in the upcoming period, according to Truist is $18 based on the research report published on January 29, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $26. The rating they have provided for LRMR stocks is “Outperform” according to the report published on October 16th, 2024.
Wedbush gave a rating of “Outperform” to LRMR, setting the target price at $22 in the report published on October 03rd of the previous year.
LRMR Trading at -27.98% from the 50-Day Moving Average
After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.64% of loss for the given period.
Volatility was left at 8.54%, however, over the last 30 days, the volatility rate increased by 9.08%, as shares sank -24.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.84% lower at present.
During the last 5 trading sessions, LRMR fell by -10.59%, which changed the moving average for the period of 200-days by -76.03% in comparison to the 20-day moving average, which settled at $2.74. In addition, Larimar Therapeutics Inc saw -41.09% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LRMR
The total capital return value is set at -0.36. Equity return is now at value -44.50, with -40.11 for asset returns.
Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -10.87.
Currently, EBITDA for the company is -41.45 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.10.
Conclusion
In summary, Larimar Therapeutics Inc (LRMR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
